{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:37:02Z","timestamp":1792143422636,"version":"4.4.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 824, Project Z1"],"award-info":[{"award-number":["SFB 824, Project Z1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To investigate whether modifications of prostate-specific membrane antigen (PSMA)-targeted radiolabeled urea-based inhibitors could reduce salivary gland uptake and thus improve tumor-to-salivary gland ratios, several analogs of a high affinity PSMA ligand were synthesized and evaluated in in vitro and in vivo studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Binding motifs were synthesized \u2018on-resin\u2019 or, when not practicable, in solution. Peptide chain elongations were performed according to optimized standard protocols via solid-phase peptide synthesis. In vitro experiments were performed using PSMA<jats:sup>+<\/jats:sup> LNCaP cells. In vivo studies as well as <jats:italic>\u03bc<\/jats:italic>SPECT\/CT scans were conducted with male LNCaP tumor xenograft-bearing CB17-SCID mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PSMA ligands with A) modifications within the central Zn<jats:sup>2+<\/jats:sup>-binding unit, B) proinhibitor motifs and C) substituents &amp; bioisosteres of the P1\u2032-\u03b3-carboxylic acid were synthesized and evaluated. Modifications within the central Zn<jats:sup>2+<\/jats:sup>-binding unit of PSMA-10 (Glu-urea-Glu) provided three compounds. Thereof, only <jats:sup>nat<\/jats:sup>Lu-carbamate I (<jats:sup>nat<\/jats:sup>Lu-<jats:bold>3<\/jats:bold>) exhibited high affinity (IC<jats:sub>50<\/jats:sub>\u2009=\u20097.1\u2009\u00b1\u20090.7\u2009nM), but low tumor uptake (5.31\u2009\u00b1\u20090.94% ID\/g, 1\u2009h p.i. and 1.20\u2009\u00b1\u20090.55% ID\/g, 24\u2009h p.i.). All proinhibitor motif-based ligands (three in total) exhibited low binding affinities (&gt;\u20091\u2009\u03bcM), no notable internalization and very low tumor uptake (&lt;\u20090.50% ID\/g). In addition, four compounds with P1\u2032-\u0263-carboxylate substituents were developed and evaluated. Thereof, only tetrazole derivative <jats:sup>nat<\/jats:sup>Lu-<jats:bold>11<\/jats:bold> revealed high affinity (IC<jats:sub>50<\/jats:sub>\u2009=\u200916.4\u2009\u00b1\u20093.8\u2009nM), but also this inhibitor showed low tumor uptake (3.40\u2009\u00b1\u20090.63% ID\/g, 1\u2009h p.i. and 0.68\u2009\u00b1\u20090.16% ID\/g, 24\u2009h p.i.). Salivary gland uptake in mice remained at an equally low level for all compounds (between 0.02\u2009\u00b1\u20090.00% ID\/g and 0.09\u2009\u00b1\u20090.03% ID\/g), wherefore apparent tumor-to-submandibular gland and tumor-to-parotid gland ratios for the modified peptides were distinctly lower (factor 8\u201345) than for [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-10 at 24\u2009h p.i.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The investigated compounds could not compete with the in vivo characteristics of the EuE-based PSMA inhibitor [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-10. Although two derivatives (<jats:bold>3<\/jats:bold> and <jats:bold>11<\/jats:bold>) were found to exhibit high affinities towards LNCaP cells, tumor uptake at 24\u2009h p.i. was considerably low, while uptake in salivary glands remained unaffected. Optimization of the established animal model should be envisaged to enable a clear identification of PSMA-targeting radioligands with improved tumor-to-salivary gland ratios in future studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41181-021-00124-1","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T17:03:30Z","timestamp":1614359010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0072-9769","authenticated-orcid":false,"given":"Veronika Barbara","family":"Felber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Amando","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"issue":"2","key":"124_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"124_CR2","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate Cancer. J Clin Oncol. 2005;23(21):4591\u2013601.","journal-title":"J Clin Oncol"},{"issue":"2","key":"124_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bmc.2018.11.022","volume":"27","author":"C Barinka","year":"2019","unstructured":"Barinka C, Novakova Z, Hin N, Bim D, Ferraris DV, Duvall B, et al. Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors. Bioorg Med Chem. 2019;27(2):255\u201364.","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"124_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.0022-3042.2001.00715.x","volume":"80","author":"C Barinka","year":"2002","unstructured":"Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, et al. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem. 2002;80(3):477\u201387.","journal-title":"J Neurochem"},{"issue":"6","key":"124_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2174\/092986712799034888","volume":"19","author":"C Barinka","year":"2012","unstructured":"Barinka C, Rojas C, Slusher B, Pomper M. Glutamate Carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate Cancer. Curr Med Chem. 2012;19(6):856\u201370.","journal-title":"Curr Med Chem"},{"issue":"3","key":"124_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2967\/jnumed.112.111203","volume":"54","author":"JA Barrett","year":"2013","unstructured":"Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of 2 high-affinity PSMA-avid Small molecules for imaging prostate Cancer. J Nucl Med. 2013;54(3):380\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"124_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","volume":"52","author":"RP Baum","year":"2018","unstructured":"Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, et al. Injection of Botulinum toxin for preventing salivary gland toxicity after PSMA Radioligand therapy: an empirical proof of a promising concept. Nucl Med Mol Imaging. 2018;52(1):80\u20131.","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"124_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2967\/jnumed.118.220715","volume":"60","author":"SC Behr","year":"2019","unstructured":"Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, et al. Phase I study of CTT1057, an 18F-labeled imaging agent with Phosphoramidate Core targeting prostate-specific membrane antigen in prostate Cancer. J Nucl Med. 2019;60(7):910\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"124_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and Endoradiotherapy of prostate Cancer. J Nucl Med. 2015;56(6):914\u201320.","journal-title":"J Nucl Med"},{"issue":"4","key":"124_CR10","first-page":"247","volume":"8","author":"R Chakravarty","year":"2018","unstructured":"Chakravarty R, Siamof CM, Dash A, Cai W. Targeted \u03b1-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. Am J Nucl Med Mol Imaging. 2018;8(4):247\u201367.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"124_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fonc.2018.00653","volume":"8","author":"A Cimadamore","year":"2018","unstructured":"Cimadamore A, Scarpelli M, Montironi R, Cheng M, Santoni M, Battelli N, et al. New prostate Cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen. Front Oncol. 2018;8:653.","journal-title":"Front Oncol"},{"issue":"140","key":"124_CR12","doi-asserted-by":"publisher","first-page":"140ra86","DOI":"10.1126\/scitranslmed.3003886","volume":"4","author":"SR Denmeade","year":"2012","unstructured":"Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012;4(140):140ra86 13 pp.","journal-title":"Sci Transl Med"},{"issue":"1","key":"124_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-017-0023-y","volume":"2","author":"I Dude","year":"2017","unstructured":"Dude I, Zhang Z, Rousseau J, Hundal-Jabal N, Colpo N, Merkens H, et al. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharmacy Chem. 2017;2(1):4.","journal-title":"EJNMMI Radiopharmacy Chem"},{"issue":"18","key":"124_CR14","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.7150\/thno.20586","volume":"7","author":"E Eppard","year":"2017","unstructured":"Eppard E, de la Fuente A, Bene\u0161ov\u00e1 M, Khawar A, Bundschuh RA, G\u00e4rtner FC, et al. Clinical translation and first in-human use of [(44)Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate Cancer. Theranostics. 2017;7(18):4359\u201369.","journal-title":"Theranostics."},{"issue":"9","key":"124_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2174\/092986712799462658","volume":"19","author":"DV Ferraris","year":"2012","unstructured":"Ferraris DV, Shukla K, Tsukamoto T. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. Curr Med Chem. 2012;19(9):1282\u201394.","journal-title":"Curr Med Chem"},{"issue":"3","key":"124_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528\u201339.","journal-title":"J Cell Biochem"},{"issue":"7","key":"124_CR17","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1021\/jm501371s","volume":"58","author":"AK Ghosh","year":"2015","unstructured":"Ghosh AK, Brindisi M. Organic Carbamates in drug design and medicinal chemistry. J Med Chem. 2015;58(7):2895\u2013940.","journal-title":"J Med Chem"},{"issue":"7","key":"124_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","volume":"59","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, et al. Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med. 2018;59(7):1076\u201380.","journal-title":"J Nucl Med"},{"issue":"11","key":"124_CR19","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/S0968-0896(02)00239-0","volume":"10","author":"RJ Herr","year":"2002","unstructured":"Herr RJ. 5-substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg Med Chem. 2002;10(11):3379\u201393.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"124_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.115.156133","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester H-J, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56(6):855\u201361.","journal-title":"J Nucl Med"},{"issue":"5B","key":"124_CR21","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927\u201335.","journal-title":"Anticancer Res"},{"key":"124_CR22","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Prostate+Cancer&term=PSMA&cntry=&state=&city=&dist=. Accessed on 23 Sept 2020."},{"key":"124_CR23","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03511664?term=PSMA&cond=Prostate+Cancer&phase=2&draw=5&rank=2. Accessed on 23 Sept 2020."},{"issue":"48","key":"124_CR24","doi-asserted-by":"publisher","first-page":"17053","DOI":"10.1021\/ja104204z","volume":"132","author":"S-H Hyun","year":"2010","unstructured":"Hyun S-H, Kim H-K, Kim J-M, Thompson DH. Oriented insertion of phi29 N-Hexahistidine-tagged gp10 connector protein assemblies into C20BAS Bolalipid membrane vesicles. J Am Chem Soc. 2010;132(48):17053\u20135.","journal-title":"J Am Chem Soc"},{"issue":"7","key":"124_CR25","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807\u201311.","journal-title":"Cancer Res"},{"issue":"5","key":"124_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","volume":"125","author":"TJW Klein Nulent","year":"2018","unstructured":"Klein Nulent TJW, Valstar MH, de Keizer B, Willems SM, Smit LA, Al-Mamgani A, et al. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):478\u201386.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"9","key":"124_CR27","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/2211-5463.12276","volume":"7","author":"T Knedlik","year":"2017","unstructured":"Knedlik T, Vorlova B, Navratil V, Tykvart J, Sedlak F, Vaculin S, et al. Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII. FEBS Open Bio. 2017;7(9):1362\u201378.","journal-title":"FEBS Open Bio"},{"issue":"7","key":"124_CR28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/jm0306226","volume":"47","author":"AP Kozikowski","year":"2004","unstructured":"Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, et al. Synthesis of urea-based inhibitors as active site probes of glutamate Carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004;47(7):1729\u201338.","journal-title":"J Med Chem"},{"issue":"12","key":"124_CR29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate Cancer. J Nucl Med. 2016a;57(12):1941\u20134.","journal-title":"J Nucl Med"},{"issue":"10","key":"124_CR30","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate Cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624\u201331.","journal-title":"J Nucl Med"},{"issue":"5","key":"124_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate Cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795\u2013802.","journal-title":"J Nucl Med"},{"issue":"8","key":"124_CR32","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate Cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016b;57(8):1170\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"124_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1021\/mp9000712","volume":"6","author":"SA Kularatne","year":"2009","unstructured":"Kularatne SA, Zhou Z, Yang J, Post CB, Low PS. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-Radioimaging agents. Mol Pharm. 2009;6(3):790\u2013800.","journal-title":"Mol Pharm"},{"issue":"7","key":"124_CR34","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1021\/acs.jmedchem.5b01963","volume":"59","author":"P Lassalas","year":"2016","unstructured":"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, et al. Structure property relationships of carboxylic acid Isosteres. J Med Chem. 2016;59(7):3183\u2013203.","journal-title":"J Med Chem"},{"issue":"19","key":"124_CR35","first-page":"6423","volume":"50","author":"AD Lopes","year":"1990","unstructured":"Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific Immunoconjugate CYT-356 derived from Antiprostate monoclonal antibody 7E11-C5. Cancer Res. 1990;50(19):6423\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"124_CR36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.bmcl.2012.09.014","volume":"23","author":"G Lu","year":"2013","unstructured":"Lu G, Maresca KP, Hillier SM, Zimmerman CN, Eckelman WC, Joyal JL, et al. Synthesis and SAR of 99mTc\/re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. 2013;23(5):1557\u201363.","journal-title":"Bioorg Med Chem Lett"},{"key":"124_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1055\/s-1979-28761","volume":"8","author":"LJ Mathias","year":"1979","unstructured":"Mathias LJ. Esterification and alkylation reactions employing isoureas. Synthesis. 1979;8:561\u201376.","journal-title":"Synthesis."},{"issue":"4","key":"124_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA\u2013PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226\u201335.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"124_CR39","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4161\/cbt.3.6.846","volume":"3","author":"A Mhaka","year":"2004","unstructured":"Mhaka A, Gady AM, Rosen DM, Lo K-M, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther. 2004;3(6):551\u20138.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"124_CR40","first-page":"917","volume":"17","author":"M Mosayebnia","year":"2018","unstructured":"Mosayebnia M, Rezaeianpour S, Rikhtechi P, Hajimahdi Z, Beiki D, Kobarfard F, et al. Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods. Iran J Pharm Res. 2018;17(3):917\u201326.","journal-title":"Iran J Pharm Res"},{"issue":"supplement 1","key":"124_CR41","first-page":"1557","volume":"60","author":"SW Oh","year":"2019","unstructured":"Oh SW, Wurzer A, Wester H-J, Teoh EJ, Oh S, Langbein T, et al. Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of Novel Radiohybrid PSMA, (18)F- rhPSMA-7, in Patients with Prostate Cancer. J Nucl Med. 2019;60(supplement 1):1557.","journal-title":"J Nucl Med"},{"issue":"2","key":"124_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pros.10319","volume":"58","author":"DS O'Keefe","year":"2004","unstructured":"O'Keefe DS, Bacich DJ, Heston WDW. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004;58(2):200\u201310.","journal-title":"Prostate"},{"issue":"21","key":"124_CR43","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1021\/jm200807m","volume":"54","author":"A Plechanovova","year":"2011","unstructured":"Plechanovova A, Byun Y-J, Alquicer G, Skultetyova L, Mlcochova P, Nemcova A, et al. Novel substrate-based inhibitors of human glutamate Carboxypeptidase II with enhanced Lipophilicity. J Med Chem. 2011;54(21):7535\u201346.","journal-title":"J Med Chem"},{"issue":"1","key":"124_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate Cancer patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"issue":"1","key":"124_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","volume":"46","author":"H Rathke","year":"2019","unstructured":"Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019;46(1):139\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"124_CR46","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.urolonc.2013.09.003","volume":"32","author":"BT Ristau","year":"2014","unstructured":"Ristau BT, Bacich DJ, O'Keefe DS. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32(3):272\u20139.","journal-title":"Urol Oncol"},{"issue":"1","key":"124_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-018-0382-8","volume":"8","author":"S Robu","year":"2018","unstructured":"Robu S, Schmidt A, Eiber M, Schottelius M, G\u00fcnther T, Hooshyar Yousefi B, et al. Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007. EJNMMI Res. 2018;8(1):30.","journal-title":"EJNMMI Res"},{"issue":"12","key":"124_CR48","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2967\/jnumed.118.215350","volume":"59","author":"E Rousseau","year":"2018","unstructured":"Rousseau E, Lau J, Kuo H-T, Zhang Z, Merkens H, Hundal-Jabal N, et al. Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate Cancer model. J Nucl Med. 2018;59(12):1865\u20138.","journal-title":"J Nucl Med"},{"issue":"7","key":"124_CR49","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2967\/jnumed.115.154336","volume":"56","author":"SP Rowe","year":"2015","unstructured":"Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. 18F-DCFBC PET\/CT for PSMA-based detection and characterization of primary prostate Cancer. J Nucl Med. 2015;56(7):1003\u201310.","journal-title":"J Nucl Med"},{"issue":"4","key":"124_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/cbr.2019.3079","volume":"35","author":"J Roy","year":"2020","unstructured":"Roy J, Warner BM, Basuli F, Zhang X, Wong K, Pranzatelli T, et al. Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human Primates and rodents. Cancer Biother Radiopharm. 2020;35(4):284\u201391.","journal-title":"Cancer Biother Radiopharm"},{"issue":"9","key":"124_CR51","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","volume":"60","author":"NJ Rupp","year":"2019","unstructured":"Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Topfer AT, Muller JM, et al. First clinicopathologic evidence of a non-PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60(9):1270\u20136.","journal-title":"J Nucl Med"},{"issue":"7","key":"124_CR52","doi-asserted-by":"publisher","first-page":"8278","DOI":"10.1021\/acsomega.8b00790","volume":"3","author":"A Schmidt","year":"2018","unstructured":"Schmidt A, Wirtz M, F\u00e4rber SF, Osl T, Beck R, Schottelius M, et al. Effect of Carbohydration on the Theranostic tracer PSMA I&T. ACS Omega. 2018;3(7):8278\u201387.","journal-title":"ACS Omega"},{"issue":"22","key":"124_CR53","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1021\/jo0006573","volume":"65","author":"I Shin","year":"2000","unstructured":"Shin I, Lee M-R, Lee J, Jung M, Lee W, Yoon J. Synthesis of optically active Phthaloyl d-Aminooxy acids from l-amino acids or l-Hydroxy acids as building blocks for the preparation of Aminooxy peptides. J Org Chem. 2000;65(22):7667\u201375.","journal-title":"J Org Chem"},{"issue":"2","key":"124_CR54","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/nprot.2006.175","volume":"1","author":"JK Sosabowski","year":"2006","unstructured":"Sosabowski JK, Mather SJ. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat Protoc. 2006;1(2):972\u20136.","journal-title":"Nat Protoc"},{"issue":"18","key":"124_CR55","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177\u2013labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate Cancer. Clin Cancer Res. 2013;19(18):5182\u201391.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"124_CR56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ph12010018","volume":"12","author":"R T\u00f6nnesmann","year":"2019","unstructured":"T\u00f6nnesmann R, Meyer PT, Eder M, Baranski A-C. [(177)Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals (Basel). 2019;12(1):18.","journal-title":"Pharmaceuticals (Basel)"},{"key":"124_CR57","doi-asserted-by":"crossref","unstructured":"Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5):552\u20138.","DOI":"10.1002\/ijc.2910620511"},{"issue":"11","key":"124_CR58","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","volume":"55","author":"S Vallabhajosula","year":"2014","unstructured":"Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, et al. 99mTc-labeled Small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate Cancer. J Nucl Med. 2014;55(11):1791\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"124_CR59","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/RLU.0000000000002561","volume":"44","author":"L van Kalmthout","year":"2019","unstructured":"van Kalmthout L, Braat A, Lam M, van Leeuwaarde R, Krijger G, Ververs T, et al. First experience with 177Lu-PSMA-617 therapy for advanced prostate Cancer in the Netherlands. Clin Nucl Med. 2019;44(6):446\u201351.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"124_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","volume":"8","author":"LWM van Kalmthout","year":"2018","unstructured":"van Kalmthout LWM, Lam MGEH, de Keizer B, Krijger GC, Ververs TFT, de Roos R, et al. Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands. EJNMMI Res. 2018;8(1):56.","journal-title":"EJNMMI Res"},{"issue":"10","key":"124_CR61","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1158\/0008-5472.CAN-08-3781","volume":"69","author":"AL V\u0101vere","year":"2009","unstructured":"V\u0101vere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA, et al. A novel Technology for the Imaging of acidic prostate tumors by positron emission tomography. Cancer Res. 2009;69(10):4510\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"124_CR62","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bmcl.2009.10.061","volume":"20","author":"H Wang","year":"2010","unstructured":"Wang H, Byun Y, Barinka C, Pullambhatla M, Bhang H-EC, Fox JJ, et al. Bioisosterism of urea-based GCPII inhibitors: synthesis and structure\u2013activity relationship studies. Bioorg Med Chem Lett. 2010;20(1):392\u20137.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"124_CR63","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","volume":"56","author":"M Weineisen","year":"2015","unstructured":"Weineisen M, Schottelius M, Wester H-J, Simecek J, Baum RP, Kulkarni HR, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted Theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169\u201376.","journal-title":"J Nucl Med"},{"issue":"1","key":"124_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","volume":"4","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester H-J. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):63.","journal-title":"EJNMMI Res"},{"issue":"5","key":"124_CR65","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/pros.21090","volume":"70","author":"P Wolf","year":"2010","unstructured":"Wolf P, Freudenberg N, B\u00fchler P, Alt K, Schultze-Seemann W, Wetterauer U, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562\u20139.","journal-title":"Prostate"},{"issue":"5","key":"124_CR66","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","volume":"61","author":"A Wurzer","year":"2020","unstructured":"Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020;61(5):735\u201342.","journal-title":"J Nucl Med"},{"issue":"1","key":"124_CR67","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1021\/acs.jmedchem.5b01268","volume":"59","author":"X Yang","year":"2016","unstructured":"Yang X, Mease RC, Pullambhatla M, Lisok A, Chen Y, Foss CA, et al. [18F]Fluorobenzoyllysinepentanedioic acid Carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA). J Med Chem. 2016;59(1):206\u201318.","journal-title":"J Med Chem"},{"issue":"10","key":"124_CR68","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2967\/jnumed.119.226449","volume":"60","author":"B Yilmaz","year":"2019","unstructured":"Yilmaz B, Nisli S, Ergul N, Gursu RU, Acikgoz O, \u00c7ermik TF. Effect of external cooling on 177Lu-PSMA uptake by the parotid glands. J Nucl Med. 2019;60(10):1388\u201393.","journal-title":"J Nucl Med"},{"issue":"7","key":"124_CR69","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124I\/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"48","key":"124_CR70","doi-asserted-by":"publisher","first-page":"9997","DOI":"10.1016\/j.tet.2009.09.113","volume":"65","author":"D-W Zhang","year":"2009","unstructured":"Zhang D-W, Luo Z, Liu G-J, Weng L-H. \u03b1 N-O turn induced by fluorinated \u03b1-aminoxy diamide: synthesis and conformational studies. Tetrahedron. 2009;65(48):9997\u201310001.","journal-title":"Tetrahedron."},{"key":"124_CR71","doi-asserted-by":"crossref","first-page":"153303381983075","DOI":"10.1177\/1533033819830758","volume":"18","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Li J, Xu X, Zhao M, Zhang B, Deng S, et al. 64Cu-based radiopharmaceuticals in molecular imaging. Technol Cancer Res Treat. 2019;18:1533033819830758.","journal-title":"Technol Cancer Res Treat"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-021-00124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41181-021-00124-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-021-00124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T17:06:57Z","timestamp":1614359217000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-021-00124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1186\/s41181-021-00124-1","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with general animal welfare regulations in Germany (German animal protection act, as amended on 18.05.2018, Art. 141\u2009G v. 29.3.2017 I 626, approval no. 55.2\u20131-54-2532-71-13) and the institutional guidelines for the care and use of animals. This article does not contain any studies with human participants performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HJW is listed as inventor in the patent application for PSMA. HJW is founder and shareholder of Scintomics GmbH, Fuerstenfeldbruck, Germany. No other potential conflicts of interest relevant to this article exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}